三阴性乳腺癌的雄激素受体状态:是否与临床病理特征相关?

IF 3.3 4区 医学 Q2 ONCOLOGY
Alex L Dubrava, Pan Su Pyae Kyaw, Joseph Newman, Jarrad Pringle, Justin Westhuyzen, Gina La Hera Fuentes, Thomas P Shakespeare, Renukadas Sakalkale, Noel J Aherne
{"title":"三阴性乳腺癌的雄激素受体状态:是否与临床病理特征相关?","authors":"Alex L Dubrava,&nbsp;Pan Su Pyae Kyaw,&nbsp;Joseph Newman,&nbsp;Jarrad Pringle,&nbsp;Justin Westhuyzen,&nbsp;Gina La Hera Fuentes,&nbsp;Thomas P Shakespeare,&nbsp;Renukadas Sakalkale,&nbsp;Noel J Aherne","doi":"10.2147/BCTT.S405719","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Triple negative breast cancer (TNBC) is a breast carcinoma subtype that neither expresses estrogen (ER) and progesterone receptors (PR) nor the human epidermal growth factor receptor 2 (HER2). Patients with TNBC have been shown to have poorer outcomes mainly owing to the limited treatment options available. However, some studies have shown TNBC tumors expressing androgen receptors (AR), raising hopes of its prognostic role.</p><p><strong>Patients and methods: </strong>This retrospective study investigated the expression of AR in TNBC and its relationship with known patient demographics, tumor and survival characteristics. From the records of 205 TNBC patients, 36 had available archived tissue samples eligible for AR staining. For statistical purposes, tumors were classified as either \"positive\" or \"negative\" for AR expression. The nuclear expression of AR was scored by measuring the percentage of stained tumor cells and its staining intensity.</p><p><strong>Results: </strong>AR was expressed by 50% of the tissue samples in our TNBC cohort. The relationship between AR status with age at the time of TNBC diagnosis was statistically significant, with all AR positive TNBC patients being greater than 50 years old (vs 72.2% in AR negative TNBC). Also, the relationship between AR status and type of surgery received was statistically significant. There were no statistically significant associations between AR status with other tumor characteristics including \"TNM status\", tumor grade or treatments received. There was no statistically significant difference in median survival between AR negative and AR positive TNBC patients (3.5 vs 3.1 years; p = 0.581). The relationship between OS time and AR status (p = 0.581), type of surgery (p = 0.061) and treatments (p = 0.917) were not statistically significant.</p><p><strong>Conclusion: </strong>The androgen receptor may be an important prognostic marker in TNBC, with further research warranted. This research may benefit future studies investigating receptor-targeted therapies in TNBC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/72/bctt-15-359.PMC10184857.pdf","citationCount":"1","resultStr":"{\"title\":\"Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?\",\"authors\":\"Alex L Dubrava,&nbsp;Pan Su Pyae Kyaw,&nbsp;Joseph Newman,&nbsp;Jarrad Pringle,&nbsp;Justin Westhuyzen,&nbsp;Gina La Hera Fuentes,&nbsp;Thomas P Shakespeare,&nbsp;Renukadas Sakalkale,&nbsp;Noel J Aherne\",\"doi\":\"10.2147/BCTT.S405719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Triple negative breast cancer (TNBC) is a breast carcinoma subtype that neither expresses estrogen (ER) and progesterone receptors (PR) nor the human epidermal growth factor receptor 2 (HER2). Patients with TNBC have been shown to have poorer outcomes mainly owing to the limited treatment options available. However, some studies have shown TNBC tumors expressing androgen receptors (AR), raising hopes of its prognostic role.</p><p><strong>Patients and methods: </strong>This retrospective study investigated the expression of AR in TNBC and its relationship with known patient demographics, tumor and survival characteristics. From the records of 205 TNBC patients, 36 had available archived tissue samples eligible for AR staining. For statistical purposes, tumors were classified as either \\\"positive\\\" or \\\"negative\\\" for AR expression. The nuclear expression of AR was scored by measuring the percentage of stained tumor cells and its staining intensity.</p><p><strong>Results: </strong>AR was expressed by 50% of the tissue samples in our TNBC cohort. The relationship between AR status with age at the time of TNBC diagnosis was statistically significant, with all AR positive TNBC patients being greater than 50 years old (vs 72.2% in AR negative TNBC). Also, the relationship between AR status and type of surgery received was statistically significant. There were no statistically significant associations between AR status with other tumor characteristics including \\\"TNM status\\\", tumor grade or treatments received. There was no statistically significant difference in median survival between AR negative and AR positive TNBC patients (3.5 vs 3.1 years; p = 0.581). The relationship between OS time and AR status (p = 0.581), type of surgery (p = 0.061) and treatments (p = 0.917) were not statistically significant.</p><p><strong>Conclusion: </strong>The androgen receptor may be an important prognostic marker in TNBC, with further research warranted. This research may benefit future studies investigating receptor-targeted therapies in TNBC.</p>\",\"PeriodicalId\":9106,\"journal\":{\"name\":\"Breast Cancer : Targets and Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/72/bctt-15-359.PMC10184857.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer : Targets and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/BCTT.S405719\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S405719","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:三阴性乳腺癌(Triple negative breast cancer, TNBC)是一种既不表达雌激素受体(ER)和孕激素受体(PR),也不表达人表皮生长因子受体2 (HER2)的乳腺癌亚型。TNBC患者的预后较差,主要是由于可用的治疗方案有限。然而,一些研究表明TNBC肿瘤表达雄激素受体(AR),提高了其预后作用的希望。患者和方法:本回顾性研究探讨了AR在TNBC中的表达及其与已知患者人口统计学、肿瘤和生存特征的关系。从205例TNBC患者的记录中,有36例具有可用于AR染色的存档组织样本。出于统计目的,肿瘤被分类为AR表达“阳性”或“阴性”。通过测定染色的肿瘤细胞百分比及其染色强度,对AR的核表达进行评分。结果:在我们的TNBC队列中,50%的组织样本表达了AR。AR状态与TNBC诊断时年龄之间的关系具有统计学意义,所有AR阳性TNBC患者年龄均大于50岁(而AR阴性TNBC患者年龄为72.2%)。此外,AR状态与所接受手术类型之间的关系具有统计学意义。AR状态与其他肿瘤特征(包括TNM状态、肿瘤分级或接受的治疗)之间没有统计学上的显著关联。AR阴性和AR阳性TNBC患者的中位生存期无统计学差异(3.5年vs 3.1年;P = 0.581)。OS时间与AR状态(p = 0.581)、手术类型(p = 0.061)、治疗方式(p = 0.917)的关系均无统计学意义。结论:雄激素受体可能是TNBC的重要预后指标,值得进一步研究。这项研究可能有助于未来研究TNBC的受体靶向治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?

Purpose: Triple negative breast cancer (TNBC) is a breast carcinoma subtype that neither expresses estrogen (ER) and progesterone receptors (PR) nor the human epidermal growth factor receptor 2 (HER2). Patients with TNBC have been shown to have poorer outcomes mainly owing to the limited treatment options available. However, some studies have shown TNBC tumors expressing androgen receptors (AR), raising hopes of its prognostic role.

Patients and methods: This retrospective study investigated the expression of AR in TNBC and its relationship with known patient demographics, tumor and survival characteristics. From the records of 205 TNBC patients, 36 had available archived tissue samples eligible for AR staining. For statistical purposes, tumors were classified as either "positive" or "negative" for AR expression. The nuclear expression of AR was scored by measuring the percentage of stained tumor cells and its staining intensity.

Results: AR was expressed by 50% of the tissue samples in our TNBC cohort. The relationship between AR status with age at the time of TNBC diagnosis was statistically significant, with all AR positive TNBC patients being greater than 50 years old (vs 72.2% in AR negative TNBC). Also, the relationship between AR status and type of surgery received was statistically significant. There were no statistically significant associations between AR status with other tumor characteristics including "TNM status", tumor grade or treatments received. There was no statistically significant difference in median survival between AR negative and AR positive TNBC patients (3.5 vs 3.1 years; p = 0.581). The relationship between OS time and AR status (p = 0.581), type of surgery (p = 0.061) and treatments (p = 0.917) were not statistically significant.

Conclusion: The androgen receptor may be an important prognostic marker in TNBC, with further research warranted. This research may benefit future studies investigating receptor-targeted therapies in TNBC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
40
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信